105 reports of this reaction
3.1% of all BENZALKONIUM CHLORIDE 0.13% reports
#9 most reported adverse reaction
HEPATOTOXICITY is the #9 most commonly reported adverse reaction for BENZALKONIUM CHLORIDE 0.13%, manufactured by Meijer, Inc.. There are 105 FDA adverse event reports linking BENZALKONIUM CHLORIDE 0.13% to HEPATOTOXICITY. This represents approximately 3.1% of all 3,369 adverse event reports for this drug.
Patients taking BENZALKONIUM CHLORIDE 0.13% who experience hepatotoxicity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEPATOTOXICITY is moderately reported among BENZALKONIUM CHLORIDE 0.13% users, representing a notable but not dominant share of adverse events.
In addition to hepatotoxicity, the following adverse reactions have been reported for BENZALKONIUM CHLORIDE 0.13%:
The following drugs have also been linked to hepatotoxicity in FDA adverse event reports:
HEPATOTOXICITY has been reported as an adverse event in 105 FDA reports for BENZALKONIUM CHLORIDE 0.13%. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEPATOTOXICITY accounts for approximately 3.1% of all adverse event reports for BENZALKONIUM CHLORIDE 0.13%, making it a notable side effect.
If you experience hepatotoxicity while taking BENZALKONIUM CHLORIDE 0.13%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.